Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05QOL
|
|||
| Former ID |
DIB001689
|
|||
| Drug Name |
Polatuzumab vedotin
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Approved | [1] | |
| Follicular lymphoma [ICD-11: 2A80] | Phase 2 | [2] | ||
| Haematological malignancy [ICD-11: 2B33.Y] | Phase 2 | [3] | ||
| Company |
Genentech
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell-specific glycoprotein B29 (CD79B) | Target Info | . | [1] |
| KEGG Pathway | B cell receptor signaling pathway | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| Leptin Signaling Pathway | ||||
| Panther Pathway | B cell activation | |||
| Pathway Interaction Database | BCR signaling pathway | |||
| Reactome | Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||
| WikiPathways | Signaling by the B Cell Receptor (BCR) | |||
| B Cell Receptor Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.